Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Alan B Lancz & Associates Inc.

Alan B Lancz & Associates Inc. decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 10.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,450 shares of the medical equipment provider’s stock after selling 500 shares during the quarter. Alan B Lancz & Associates Inc.’s holdings in Hologic were worth $321,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Wolff Wiese Magana LLC acquired a new position in shares of Hologic in the 3rd quarter worth $25,000. General Partner Inc. acquired a new stake in Hologic during the 4th quarter worth about $26,000. First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Sunbelt Securities Inc. acquired a new position in shares of Hologic in the second quarter worth about $37,000. Finally, Cromwell Holdings LLC increased its position in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.5 %

HOLX stock opened at $71.02 on Friday. The firm has a market cap of $16.03 billion, a PE ratio of 21.33, a PEG ratio of 2.43 and a beta of 0.97. Hologic, Inc. has a 1 year low of $68.61 and a 1 year high of $84.67. The company has a fifty day simple moving average of $74.01 and a 200 day simple moving average of $78.25. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.89 earnings per share. Sell-side analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Raymond James upped their price target on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, UBS Group increased their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Insiders Place Their Bets

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.